Del Rosso James Q, Tanghetti Emil
Dr. Del Rosso is Research Director at JDR Dermatology Research in Las Vegas, Nevada, is with Thomas Dermatology in Las Vegas, Nevada, and is an adjunct clinical professor of dermatology at Touro University Nevada in Henderson, Nevada.
Dr. Tanghetti is with the Center for Dermatology and Laser Surgery in Sacramento, California.
J Clin Aesthet Dermatol. 2021 Mar;14(3):32-37. Epub 2021 Mar 1.
Rosacea is a chronic, multisymptom, inflammatory condition that affects the centrofacial skin. Facial erythema associated with rosacea can negatively impact a patient's quality of life and is often hard to treat. We sought to review the literature on the role of alpha-adrenergic receptors (α-adrenoceptors) in the context of persistent facial erythema in patients with rosacea and the use of oxymetazoline hydrochloride cream 1% as a topical treatment. PubMed was searched; search terms included "alpha adrenoceptor," "oxymetazoline," and "rosacea." Additional articles were identified from the reference lists of the results. Some α-adrenoceptor agonists have vasoconstrictive properties and may be used topically to treat persistent facial erythema in rosacea. Oxymetazoline hydrochloride cream 1% is an α-adrenoceptor agonist approved for the treatment of persistent facial erythema associated with rosacea. Based on our review, we discuss the role of the α-adrenoceptor in persistent facial erythema; provide an overview of the mechanism of action of α-adrenoceptor agonists, such as oxymetazoline, in the treatment of persistent facial erythema; and summarize the clinical development and data to date demonstrating the efficacy and safety of oxymetazoline in the treatment of persistent facial erythema associated with rosacea. The review of available literature suggests that oxymetazoline cream is well-tolerated, safe, and effective for the treatment of persistent facial erythema in rosacea and is an important component of combination treatment regimens, which are likely to become the standard of treatment for rosacea in the future.
酒渣鼻是一种影响面部中央皮肤的慢性、多症状炎症性疾病。与酒渣鼻相关的面部红斑会对患者的生活质量产生负面影响,且往往难以治疗。我们试图回顾关于α-肾上腺素能受体(α-肾上腺素受体)在酒渣鼻患者持续性面部红斑中的作用以及使用1%盐酸羟甲唑啉乳膏作为局部治疗的文献。检索了PubMed;检索词包括“α-肾上腺素受体”、“羟甲唑啉”和“酒渣鼻”。从结果的参考文献列表中识别出其他文章。一些α-肾上腺素受体激动剂具有血管收缩特性,可局部用于治疗酒渣鼻的持续性面部红斑。1%盐酸羟甲唑啉乳膏是一种被批准用于治疗与酒渣鼻相关的持续性面部红斑的α-肾上腺素受体激动剂。基于我们的综述,我们讨论α-肾上腺素受体在持续性面部红斑中的作用;概述α-肾上腺素受体激动剂(如羟甲唑啉)在治疗持续性面部红斑中的作用机制;并总结迄今为止证明羟甲唑啉治疗与酒渣鼻相关的持续性面部红斑的疗效和安全性的临床进展及数据。对现有文献的综述表明,羟甲唑啉乳膏耐受性良好、安全且有效,可用于治疗酒渣鼻的持续性面部红斑,并且是联合治疗方案的重要组成部分,联合治疗方案未来可能会成为酒渣鼻治疗的标准。